COYA (Coya Therapeutics) FCF Margin % : -120,500.00% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Coya Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-2.41 Mil. Coya Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Coya Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -120,500.00%.

As of today, Coya Therapeutics's current FCF Yield % is -11.23%.

The historical rank and industry rank for Coya Therapeutics's FCF Margin % or its related term are showing as below:

COYA' s FCF Margin % Range Over the Past 10 Years
Min: -290.21 Med: -238.32 Max: -186.42
Current: -290.21

During the past 5 years, the highest FCF Margin % of Coya Therapeutics was -186.42%. The lowest was -290.21%. And the median was -238.32%.

COYA's FCF Margin % is ranked worse than
62.1% of 1008 companies
in the Biotechnology industry
Industry Median: -127.825 vs COYA: -290.21

Coya Therapeutics FCF Margin % Historical Data

The historical data trend for Coya Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics FCF Margin % Chart

Coya Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

-186.42

-290.21

Coya Therapeutics Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial									-37.34	1,670.08	-133.26	-	-120,500.00

Competitive Comparison of Coya Therapeutics's FCF Margin %

For the Biotechnology subindustry, Coya Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coya Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Coya Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Coya Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-10.314	/	3.554
	=	-290.21 %

Coya Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-2.41	/	0.002
	=	-120,500.00 %

Coya Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Coya Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057

Website

https://www.coyatherapeutics.com

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Executives

David S Snyder	officer: Chief Financial Officer	ONE SCIENCE COURT, MADISON WI 53711
Fred Grossman	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Dieter Weinand	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Goldstein Dov A Md	director
Adrian Hepner	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Hideki Garren	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman	director, 10 percent owner, officer: Chief Executive Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc	10 percent owner	5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057